Nexalin TechnologyNXL -5.89%36 EV-to-FCF is -0.94 as of Jul. 04, 2026. GuruFocus rates NXL with a GF Score™ of 36/100 and a GF Value™ of $0.86 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Nexalin Technology ranks worse than 239234.21% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nexalin Technology's Enterprise Value is $5.07 Mil.
Nexalin Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.40 Mil. Therefore, Nexalin Technology's EV-to-FCF for today is -0.94.
The historical rank and industry rank for Nexalin Technology's EV-to-FCF or its related term are showing as below:
NXL'
s EV-to-FCF Range Over the Past 10 Years
Min: -11.39 Med: -1.21 Max: 1.9
Current: -0.94
During the past 6 years, the highest EV-to-FCF of Nexalin Technology was 1.90. The lowest was -11.39. And the median was -1.21.
NXL's EV-to-FCF is ranked worse than 100% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 23.12
vs NXL: -0.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nexalin Technology's PE Ratio (TTM) for today is calculated as:
Nexalin Technology's share price for today is $0.361.
Nexalin Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nexalin Technology EV-to-FCF Related Terms
Nexalin Technology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nexalin Technology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nexalin Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalin Technology EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nexalin Technology's EV-to-FCF falls into.
Nexalin Technology's current Enterprise Value is $5.07 Mil.
Nexalin Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexalin Technology (NXL) has a EV-to-FCF of -0.94 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nexalin Technology and its competitors. According to the industry distribution chart, Nexalin Technology ranks #999999 out of 418 companies in the Medical Devices & Instruments industry.
Is Nexalin Technology's EV-to-FCF too high?
Nexalin Technology's current EV-to-FCF is -0.94. Based on the distribution chart, Nexalin Technology ranks #999999 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nexalin Technology has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's EV-to-FCF compare to STME and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Nexalin Technology ranks #999999 out of 418 companies for EV-to-FCF. This places Nexalin Technology in the lower half of its industry. The industry median EV-to-FCF is 23.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.12, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nexalin Technology and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexalin Technology's current EV-to-FCF is -0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Possible Value Trap. The stock's GF Value™ is $0.86, compared to a current price of $0.36 — trading 58% below its estimated fair value. The current EV-to-FCF is -0.94. Nexalin Technology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nexalin Technology (NXL), the current EV-to-FCF is -0.94 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexalin Technology (NXL) Overvalued in 2026?
Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued.
The current stock price of $0.36 is trading 58% below its estimated GF Value™ of $0.86.
GuruFocus considers Nexalin Technology to be Possible Value Trap.
Key valuation signals for NXL:
EV-to-FCF: -0.94
GF Value™: $0.86 vs. price of $0.36 (58% below fair value)
No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
36GF Score
Get the complete analysis for NXL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXL has been successfully added to your 
